Infratil Limited · NZX:IFT
Infratil — Investor Day (February 2021)
20 slides from Infratil's investor day presentation, Feb 16, 2021
Slide 1: Infratil Investor Day Presentation
Infratil Investor Day Presentation 16 February 2021 Chris Munday Chief Executive
Slide 2: Introduction to Qscan
1 Introduction to Qscan
Slide 3: National network of 75+ radiology clinics across metropolitan, regional & super-regional segments
National network of 75+ radiology clinics diversified across metropolitan, regional & super-regional geographic segments Unique portfolio with strong competitive differentiation delivering catchment leadership and high barriers to scale National radiology network… Qscan clinic network as at 30-Jun-2
Slide 4: What We Excel At
What We Excel At Qscan is differentiated from its peers by having a group of highly specialised radiologists and strong management that encourage and facilitate early adoption of leading healthcare technology 100+ Highly Specialised Radiologists Clear Differentiator to Market Competitors Dr Hal Rice
Slide 5: Service Offerings Focused on High-Value Modalities
Service Offerings Focused on High-Value Modalities Qscan specialises in high-value modalities and complex procedures, in particular PET and MRI, which are critical in the diagnosis and treatment of cancer and heart diseases Modality Equipment #Machines Strategic Positioning ▪ High margin modality PE
Slide 6: Qscan's Business Model
Qscan’s Business Model Qscan provides a complete infrastructure and services platform for doctors Clinic Network Equipment Systems Infrastructure Corporate Services 75+ clinics High quality, hospital Sophisticated teleradiology Integrated and Radiographers Clinic Network grade equipment capability t
Slide 7: Introduction to the Australian Diagnostic Imaging Sector
2 Introduction to the Australian Diagnostic Imaging Sector
Slide 8: Australia Radiology Industry Snapshot
Australia Radiology Industry Snapshot Radiology in Australia has experienced a consistent industry growth of 6% p.a. Predictable industry growth Predictable, structural, long-term growth of ~6% p.a. • Radiology in an essential service and a key pillar in disease 6.4 identification, prevention and mo
Slide 9: Radiology Key Industry Drivers
Radiology Key Industry Drivers Long term sustainable growth is underpinned by a number of favourable industry conditions Driver Summary • Industry demand increases in-line with population growth Population • Australia’s population is anticipated to grow steadily in the future at 1.6% p.a. • The gene
Slide 10: Fully recovered from COVID, back to budget & growth delivered vs. PCP
Fully recovered from COVID, back to budget & growth delivered vs. PCP Qscan’s recovery was faster than the broader market, and, despite considerable COVID disruption, Qscan delivered…Underpinned 6% growth inby a number FY20 of favourable industry conditions vs. FY19 V-shaped recovery, now back to gr
Slide 11: How Qscan is set up to win
3 How Qscan is set up to win
Slide 12: Unique Qscan network with strategy built on four key growth pillars
Unique Qscan network with strategy built on four key growth pillars Qscan’s portfolio constitutes four growth pillars that provide competitive differentiation in metro areas, advantages of incumbency in regional areas, market leading PET expertise, and a scalable external reporting capability Built
Slide 13: Experienced Medical and Management Team
Experienced Medical and Management Team Qscan is led by a group of highly experienced medical and business executives Key Management Team Chris Munday Dr Mark Hansen Dr Gary Shepherd Michael Broadbent CEO, Qscan Group Qscan Group Qscan Group Group Executive, Radiologist & Chair of Radiologist & Dire
Slide 14: Platform strategy provides unique path to ongoing above-market growth
Platform strategy provides unique path to ongoing above-market growth Business transformation unlocks Platform access pto strategy high growth rovides unique markets that Qscan p at h t o o n g o i n g is best-positioned to capture a bove - m a r ke t g rowt h Exposure to fastest Deep pipeline of lo
Slide 15: Predictable trend of above-market growth and operating leverage
Predictable trend of above-market growth and operating leverage Strong embedded organic growth complemented by PET and non-PET clinic rollout Track record of 10%+ annual revenue growth to continue Operating leverage & ramp-up deliver ongoing margin expansion Revenue ($m) EBITDA ($m) and EBITDA margi
Slide 16: The Next Phase....
4 The Next Phase….
Slide 17: Delivering on our Strategic Growth Plan
Delivering on our Strategic Growth Plan Qscan has a compelling growth platform with several levers to achieve above-market growth through capturing its existing network growth, opening new clinics, executing strategic M&A, and enhancing its teleradiology capability Executing strategic metro and regi
Slide 18: Our Key Objectives
Our Key Objectives We have a multi-layered strategy to continue annual revenue growth of ~10% p.a. through • Capitalising on market growth and shift to high value modalities • Continually expanding our existing network, within both metro and regional footprints • Continuing our PET-CT clinic rollout
Slide 19: Summary
Summary • Diagnostic Imaging industry supported by predictable, stable market growth which de-risks Qscan’s growth • Organic growth supported by structural, macro-led long-term growth • Qscan benefits from market under penetration of high-value modalities (MRI,CT,PET-CT) and our experienced sub-spec
Slide 20: Questions
5 Questions